Multiple Myeloma Clinical Trials in Boston, Massachusetts

31 studies are recruiting for multiple myeloma in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 2

1. Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

   The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be rando…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Massachusetts General Hospital Cancer Center, Boston, Massachusetts

   Run by

   Massachusetts General Hospital

   See if you can join NCT05646576 on ClinicalTrials.gov

2. A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

   A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   104 in total

   Run by

   Sumitomo Pharma America, Inc.

   See if you can join NCT04988555 on ClinicalTrials.gov

3. Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

   The goal of this research study is to investigate whether a virtual, home-based, prehabilitation aerobic and resistance exercise (PARE) training program implemented 8 weeks prior to receiving autologous stem cell transplant (ASCT) for multiple myeloma participants will improve muscular strength, ph…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT05706766 on ClinicalTrials.gov

4. Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

   The main goal of this phase II study is to evaluate the overall response rate of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma. The study drugs provided for research purposes are isatuximab and belantamab mafodotin.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Massachusetts General Hospital

   See if you can join NCT05922501 on ClinicalTrials.gov

5. Collection of Samples and Clinical Data From Patients With Amyloid Diseases

   RATIONALE: Collecting and storing samples of blood, urine, tissue and data from patients with amyloid diseases to test in the laboratory may help the study of this disease in the future. PURPOSE: This research study is collecting samples from patients with amyloid diseases

   Stage

   Not phased

   Ages

   18 and older

   Site

   Boston University Cancer Research Center, Boston, Massachusetts

   Run by

   Boston Medical Center

   See if you can join NCT00898235 on ClinicalTrials.gov

6. A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   17 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT05372354 on ClinicalTrials.gov